#India Metronidazole Market Share | Explore Tumblr posts and blogs

lalsingh228-blog · 8 months ago

Text

Antiprotozoal drugs Market Projected to Show Strong Growth

Advance Market Analytics added research publication document on Worldwide Antiprotozoal drugs Market breaking major business segments and highlighting wider level geographies to get deep dive analysis on market data. The study is a perfect balance bridging both qualitative and quantitative information of Worldwide Antiprotozoal drugs market. The study provides valuable market size data for historical (Volume** & Value) from 2018 to 2022 which is estimated and forecasted till 2028*. Some are the key & emerging players that are part of coverage and have being profiled are Enzon Pharmaceuticals (United States), Sanofi (France), Pfizer, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Ipca Laboratories Ltd. (India), Merck KGaA (Germany), F. Hoffmann La-Roche Ltd. (Switzerland). Get free access to Sample Report in PDF Version along with Graphs and Figures @ https://www.advancemarketanalytics.com/sample-report/165708-global-antiprotozoal-drugs-market Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Antiprotozoal drugs Market various segments and emerging territory.

Market Drivers

Increasing prevalence of protozoan infections

Favourable government support to treat malaria

Availability of generic version at a cheaper price

Opportunities:

Ongoing research and development for Drug Development to Protozoan Diseases

Have Any Questions Regarding Global Antiprotozoal drugs Market Report, Ask Our Experts@ https://www.advancemarketanalytics.com/enquiry-before-buy/165708-global-antiprotozoal-drugs-market Analysis by Type (Chloroquine, Pyrimethamine, Mefloquine, Hydroxychloroquine, Metronidazole, Atovaquone, Others), Form (Liquid, Tablet, Injectable form), Distribution (Online Pharmacy, Offline Pharmacy)

Competitive landscape highlighting important parameters that players are gaining along with the Market Development/evolution

• % Market Share, Segment Revenue, Swot Analysis for each profiled company [Enzon Pharmaceuticals (United States), Sanofi (France), Pfizer, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Ipca Laboratories Ltd. (India), Merck KGaA (Germany), F. Hoffmann La-Roche Ltd. (Switzerland)]

• Business overview and Product/Service classification

• Product/Service Matrix [Players by Product/Service comparative analysis]

• Recent Developments (Technology advancement, Product Launch or Expansion plan, Manufacturing and R&D etc)

• Consumption, Capacity & Production by Players The regional analysis of Global Antiprotozoal drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2023-2028. Table of Content Chapter One: Industry Overview Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis Chapter Three: Production Market Analysis Chapter Four: Sales Market Analysis Chapter Five: Consumption Market Analysis Chapter Six: Production, Sales and Consumption Market Comparison Analysis Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis Chapter Eight: Competition Analysis by Players Chapter Nine: Marketing Channel Analysis Chapter Ten: New Project Investment Feasibility Analysis Chapter Eleven: Manufacturing Cost Analysis Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers Read Executive Summary and Detailed Index of full Research Study @ https://www.advancemarketanalytics.com/reports/165708-global-antiprotozoal-drugs-market Highlights of the Report • The future prospects of the global Antiprotozoal drugs market during the forecast period 2023-2028 are given in the report. • The major developmental strategies integrated by the leading players to sustain a competitive market position in the market are included in the report. • The emerging technologies that are driving the growth of the market are highlighted in the report. • The market value of the segments that are leading the market and the sub-segments are mentioned in the report. • The report studies the leading manufacturers and other players entering the global Antiprotozoal drugs market. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 [email protected]

#Global Antiprotozoal drugs Market #Antiprotozoal drugs Market Demand #Antiprotozoal drugs Market Trends #Antiprotozoal drugs Market Analysis #Antiprotozoal drugs Market Growth #Antiprotozoal drugs Market Share #Antiprotozoal drugs Market Forecast #Antiprotozoal drugs Market Challenges

0 notes

rohans18 · 1 year ago

Text

Cronkhite–Canada Syndrome Market Applications and Current Status

Global Cronkhite–Canada Syndrome Market, By Treatment ( Colonoscopy, Blood transfusion, Antibiotics, Eradication of H.pylori, Surgery, Sulfasalazine, Metronidazole, Ranitidine, Combination of Systemic Corticosteroids, Antiplasmin, Immunomodulators, and Antitumour Necrosis factor (TNF)-α agents), Symptoms (Alopecia, Hyperpigmentation, Onychodystrophy, Diarrhea, Abdominal Cramps, Cachexia, Peripheral Edema, Ecchymotic Plaques Malnutrition, Nausea and Others), Diagnosis (Erythrocyte sedimentation rate , C-reactive protein, Serum electrolyte levels, Glucose and lipid concentrations, Antinuclear factor, Serum micronutrient levels, Occult blood testing, Sudan III testing, Tests for Helicobacter pylori, Biopsy, and Radiological examination), Route of Administration (Oral, Injectable), End-Users (Clinics, Hospitals, Diagnostic centres, Surgical centres, others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Cronkhite–Canada Syndrome marketing report. The report has a lot to offer to both established and new players in the Cronkhite–Canada Syndrome industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Cronkhite–Canada Syndrome market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the Global Cronkhite–Canada Syndrome Market report are Abbott Laboratories, Allergan, Merck Sharp & Dohme Corp., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Strides Pharma Science Limited, Tocris Bioscience, Sun Pharmaceutical Industries Ltd., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-cronkhitecanada-syndrome-market

With the help of credible Cronkhite–Canada Syndrome market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Cronkhite–Canada Syndrome market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Cronkhite–Canada Syndrome Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

0 notes

techsciresearch · 4 years ago

Text

India Metronidazole Market to grow at a steady rate During the Forecast Period

Growing prevalence of diseases is expected to drive the growth of India metronidazole market.

According to TechSci Research report, “India Metronidazole Market By Type of Process (Glyoxal Process, Ethidene Diamine Process, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Route of Administration (Oral v/s Intravenous), By Form (Tablet, Capsule, Injection, Others), By Distribution Channel (Online v/s Offline), By Product Type (Prescription v/s OTC), By Application (Dracunculiasis, Giardiasis, Trichomoniasis, Amebiasis, Bacterial Vaginosis, Others), By Company, By Region, Forecast & Opportunities, FY2026”, the India metronidazole market is expected to grow at a steady rate during the forecast period on account of the extensive use of the drug in treatment of Dracunculiasis, Giardiasis, Trichomoniasis, Amebiasis, among others. Additionally, the antibiotic is present in WHO’s list of essential drugs thereby increasing its demand and use. This in turn is expected to positively influence the market growth over the next few years. Furthermore, metronidazole serves as an alternative to vancomycin in the treatment of clostridium difficile colitis. However, side effects such as loss of appetite, headache, nausea, dizziness, blurred vision, drowsiness, fever among others are observed due to the intake of metronidazole thereby hampering the market growth through FY2026. Also, the drug is not safe for use in the early stages of pregnancy. Moreover, allergic reactions and sometimes seizures are also observed in certain cases due to consumption of metronidazole. Besides, the drug is not effective against viral infections such as common cold, flu, among others.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on" India Metronidazole Market"

https://www.techsciresearch.com/report/india-metronidazole-market/7196.html

The India metronidazole market is segmented based on type of process, source, form, route of administration, distribution channel, product type, application, company and region. Based on source, the market can be split into in-house and contract manufacturing organizations. The in-house segment is expected to dominate the market on account of the presence of well-established big pharma giants and local players operating in the market. Additionally, the launch of schemes such as production linked incentive scheme for manufacturing of APIs locally in India will boost the status of domestic players thereby driving the segmental growth. Based on form, the market can be categorized into tablets, capsule, injection and others. The tablets segment is expected to dominate the market on account of the benefits such as easy availability, low cost, ability to split into two in case a low dose has to be administered, durability, long lasting effect, among others. Additionally, a single API can accommodate large dose of API as compared to a capsule. Based on distribution channel, the market can be split into online and offline. The offline segment is expected to dominate the market on account of the well established network of pharmacies in the country. The online segment is expected to register significant growth during forecast period due to the emergence of several online pharmacies and e-commerce platforms.

Unichem Laboratories Ltd., Aarey Drugs & Pharmaceuticals Ltd., Aarti Drugs Ltd., Lupin Limited, Abbott India Ltd., Atom Pharmaceuticals Pvt. Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Aristo Pharmaceuticals Pvt. Ltd., Geno Pharmaceuticals Private Limited, Torrent Pharmaceuticals Ltd. and others are some of the leading players operating in India Metronidazole market. Companies operating in the market are using organic strategies such as product launches, mergers and acquisitions and research collaborations to boost their share.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7196

Customers can also request for 10% free customization on this report.

“India metronidazole market is expected to witness growth during the forecast period on account of the growing focus of the government in making the country self-sufficient with respect to API manufacturing and drug development. With respect to this the government of India has launched few schemes and policies such as production linked incentive scheme, scheme for establishment of bulk drug parks, China plus one strategy, among others.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

“India Metronidazole Market By Type of Process (Glyoxal Process, Ethidene Diamine Process, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Route of Administration (Oral v/s Intravenous), By Form (Tablet, Capsule, Injection, Others), By Distribution Channel (Online v/s Offline), By Product Type (Prescription v/s OTC), By Application (Dracunculiasis, Giardiasis, Trichomoniasis, Amebiasis, Bacterial Vaginosis, Others), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India metronidazole market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India metronidazole market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

#India Metronidazole Market #India Metronidazole Market Size #India Metronidazole Market Share #India Metronidazole Market Growth #India Metronidazole Market Trend

0 notes

unabashedcollectivepizza · 3 years ago

Text

Heart Attack Diagnostics Current Status, Supply-Demand, Growth Opportunities and Top Players

Heart Attack Diagnostics Market Overview:

The study covers the Heart Attack Diagnostics market's most recent revenue and market trends. It stresses a market overview, definition, and structure, as well as preventative and pre-planned management. The report focuses on the factors that influence the Heart Attack Diagnostics Market, such as gross margin, cost, market share, capacity utilisation, and supply. It also aids in determining the future potential of Heart Attack Diagnostics Market in the next years. The report presents a market overview through common subjects that are highlighted with unique data based on the need. This overview aids in making decisions about how to approach the market and comprehending the industry's backdrop.

Request for free sample:

https://www.maximizemarketresearch.com/request-sample/36939

Market Scope:

Key Market Trends & Challenges:

The study analyses the primary adoption trend impacting the Heart Attack Diagnostics industry as well as issues that may stymie its expansion. Understanding these elements is critical for product planning and design, as well as commercial strategies. To assist you understand the Heart Attack Diagnostics market, this study provides a full analysis of these trends and obstacles.

Market Statistics:

The report provides the market size and share of the Heart Attack Diagnostics market. It helps in understanding the market and the report estimates upfront data and statistics that make the report a very valuable guide for individuals dealing with advertising and industry decision-making processes in the Heart Attack Diagnostics market.

Get more Report Details

https://www.maximizemarketresearch.com/market-report/global-periodontal-therapeutics-market/36939/

Segmentation:

Periodontal diseases are infections of the gums, periodontal ligament, and alveolar bone, which surround the teeth. Products used in the treatment and diagnosis of periodontal illnesses are known as periodontal therapies. Antibiotics including minocycline, metronidazole, doxycycline, and amoxicillin, as well as regionally used antibiotics like atridox, arestin, and periochip, are among these products.

Key Players:

• Den-Mat Holdings, LLC • Dexcel Pharma • Galderma S.A. • Kaken Pharmaceutical Co., Ltd. • Valeant Pharmaceuticals International, Inc • OASIS Medical • AFT Pharmaceuticals • I-Med Pharma Inc.

Regional Analysis:

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of Heart Attack Diagnostics market in these countries, which covering North America, U.S., Canada, Mexico, Europe, UK, Germany, France, Spain, Italy, Rest of Europe, Asia Pacific, China, India, Japan, Australia, South Korea, ASEAN Countries, Rest of APAC, South America, Brazil, and Middle East and Africa.

COVID-19 Impact Analysis on Heart Attack Diagnostics Market:

The report has identified detailed impact of COVID-19 on Heart Attack Diagnostics market in regions such as North America, Asia Pacific, Middle-East, Europe, and South America. The report provides Comprehensive analysis on alternatives, difficult conditions, and difficult scenarios of Heart Attack Diagnostics market during this crisis. The report briefly elaborates the advantages as well as the difficulties in terms of finance and market growth attained during the COVID-19. In addition, report offers a set of concepts, which is expected to aid readers in deciding and planning a strategy for their business.

Key Questions answered in the Heart Attack Diagnostics Market Report are:

Which product segment grabbed the largest share in the Heart Attack Diagnostics market?

How is the competitive scenario of the Heart Attack Diagnostics market?

Which are the key factors aiding the Heart Attack Diagnostics market growth?

Which region holds the maximum share in the Heart Attack Diagnostics market?

What will be the CAGR of the Heart Attack Diagnostics market during the forecast period?

Which application segment emerged as the leading segment in the Heart Attack Diagnostics market?

Which are the prominent players in the Heart Attack Diagnostics market?

What key trends are likely to emerge in the Heart Attack Diagnostics market in the coming years?

What will be the Heart Attack Diagnostics market size by 2027?

Which company held the largest share in the Heart Attack Diagnostics market?

About Us:

Maximize Market Research provides B2B and B2C research on 12000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defence and other manufacturing sectors.

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT Park Phase 2,

Pune Bangalore Highway,

Narhe, Pune, Maharashtra 411041, India.

Email: [email protected]

Phone No.: +91 20 6630 3320

Website: www.maximizemarketresearch.com

0 notes

vivekbajaj-grs · 3 years ago

Text

Global Helicobacter Pylori Diagnostics Market Size, Status and Forecast 2021-2027

Helicobacter pylori (H. pylori) is a Gram-negative, microaerobic human pathogen and H. pylori infection is strongly related with many gastroduodenal diseases including chronic active gastritis, peptic ulcer diseases, atrophic gastritis, mucosa associated lymphoid tissue (MALT) lymphoma and noncardia gastric cancer. H. pylori infection affects more than half of the adult population worldwide, but the prevalence of H pylori infection varies widely by geographic area, age, race, and socioeconomic status. Usually, the prevalence of H. pylori increases with age in most countries, however a decline in prevalence of H. pylori infection has been observed in recent decades in time trend analysis of several large populations. More than 80% of peptic ulcer diseases are caused by H. pylori infection and the estimated lifetime risk for peptic ulcer disease in H. pylori-infected patients is approximately 15%. Gastric cancer is the third leading cause of cancer-related death worldwide and H. pylori infection is responsible for 74.7% of all noncardia gastric cancer cases. Gastric cancer and peptic ulcer together cause more than a million deaths per year in the world and H. pylori infection always is an important health issue. Various diagnostic methods are developed to detect H. pylori infection and diagnostic tests with both high sensitivity and specificity, exceeding 90%, are necessary for accurate diagnosis of H. pylori infection in clinical practice. Although many diagnostic tests are available now, each method has its own advantages, disadvantages, and limitations. The choice of one method or another could be depended on availability and accessibility of diagnostic tests, level of laboratories, clinical conditions of patients, and likelihood ratio of positive and negative tests on different clinical circumstances. Diagnostic tests are usually divided into invasive (endoscopic-based) and noninvasive methods. Invasive diagnostic tests include endoscopic image, histology, rapid urease test, culture, and molecular methods. Non-invasive diagnostic tests included Non-invasive Techniques, stool antigen test, serological, and molecular examinations.

One of the key drivers witnessed in the market is the growing cost-effectiveness of diagnosis and personalized antibiotic therapy. H. pylori bacteria causes ulcer. H. pylori infection requires antibiotic therapy that includes 10-14 days treatment regimen. This treatment regimen comprises of one or two antibiotics such as amoxicillin, tetracycline, metronidazole, or clarithromycin in combination with ranitidine bismuth citrate, bismuth subsalicylate, and a proton pump inhibitor (PPI). Ulcer-related symptoms such as abdominal pain and nausea and inflammation of gastric mucosa can be cured using PPIs or H2 blockers in combination with antibiotics. The cost-effectiveness of antibiotics and the lesser duration of treatment boosts the adoption of antibiotic regimen by healthcare professionals. This in turn, will drive the demand for pre- and post-monitoring tests.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-helicobacter-pylori-diagnostics-2021-2027-637

In terms of geography, the Europe accounted for the majority market shares during 2017 and this mainly accounted to the growing prevalence of peptic ulcer disease and gastritis. The increasing patient pool looking for the early detection of symptoms and treatment is boosting the demand for helicobacter pylori diagnostics in the region. Owing to the continuous efforts of vendors to develop a vaccination for H. pylori infection and the introduction of improved diagnostic techniques, the market will continue to witness considerable growth in this region during the next four years as well.

The helicobacter pylori diagnostics market is characterized by the presence of major vendors and is highly competitive. These vendors compete against each other based on factors including pricing, product differentiation, and advancements in technology. Vendors are highly focusing on expanding their product portfolio and increasing investments in acquiring other players, which will help them increase their revenue shares. Additionally, they are also focusing on the development of vaccines and enhancing their presence in the regional and untapped markets.

Hospitals and clinics reduce the overall disease burden and promote health by offering immunoassays and molecular diagnostic techniques. These techniques enable the early diagnosis of infectious and lethal diseases. The patient pool suffering from infectious diseases such as bacterial diseases (enteric bacteria), cancer, and other life-threatening diseases highly rely on hospitals since they have tie-ups with research and developmental centers and research institutes.

Market Analysis and Insights: Global Helicobacter Pylori Diagnostics Market

The global Helicobacter Pylori Diagnostics market size is projected to reach US$ 976.2 million by 2027, from US$ 596.2 million in 2020, at a CAGR of 7.3% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Helicobacter Pylori Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Helicobacter Pylori Diagnostics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Helicobacter Pylori Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Helicobacter Pylori Diagnostics market.

Global Helicobacter Pylori Diagnostics Scope and Market Size

Helicobacter Pylori Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Helicobacter Pylori Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

Invasive Techniques

Non-invasive Techniques

Segment by Application

Hospitals and Clinics

Diagnostic Laboratories

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Sekisui Diagnostics

F. Hoffmann-La Roche

Medline Industries

Meridian Bioscience

Bio-Rad Laboratories

Thermo Fisher Scientific

Alpha Laboratories

EKF Diagnostics

Quidel

Halyard Health

Cardinal Health

Beckman Coulter

Agilent Technologies

Coris BioConcept

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-helicobacter-pylori-diagnostics-2021-2027-637

Table of content

1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Helicobacter Pylori Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Invasive Techniques 1.2.3 Non-invasive Techniques 1.3 Market by Application 1.3.1 Global Helicobacter Pylori Diagnostics Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals and Clinics 1.3.3 Diagnostic Laboratories 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Helicobacter Pylori Diagnostics Market Perspective (2016-2027) 2.2 Helicobacter Pylori Diagnostics Growth Trends by Regions 2.2.1 Helicobacter Pylori Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Helicobacter Pylori Diagnostics Historic Market Share by Regions (2016-2021) 2.2.3 Helicobacter Pylori Diagnostics Forecasted Market Size by Regions (2022-2027) 2.3 Helicobacter Pylori Diagnostics Industry Dynamic 2.3.1 Helicobacter Pylori Diagnostics Market Trends 2.3.2 Helicobacter Pylori Diagnostics Market Drivers 2.3.3 Helicobacter Pylori Diagnostics Market Challenges 2.3.4 Helicobacter Pylori Diagnostics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Helicobacter Pylori Diagnostics Players by Revenue 3.1.1 Global Top Helicobacter Pylori Diagnostics Players by Revenue (2016-2021) 3.1.2 Global

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

#HelicobacterPyloriDiagnosticsMarket

0 notes

healthcare-market · 3 years ago

Text

Balantidiasis Treatment Market Trends and Growth Factors Analysis

Balantidiasis Treatment Market: Introduction

· Balantidiasis, also known as Balantidium coli infection, is a disorder caused by Balantidium coli, an intestinal protozoan parasite. The parasite is transmitted through the fecal-oral route. Humans can be infected by the parasite by ingesting infective cysts from food and water contaminated with defecation. This infection predominantly affects the large intestine. Diarrhea, weight loss, dysentery, stomach pain, and vomiting are common side-effects of balantidiasis. The infection is observed to be prevalent in rural areas in industrially advanced and developing regions due to water pollution caused by fecal matter of humans and/or pigs. Provision of safe and clean drinking water can prevent the infection from spreading from one person to the other. Anti-infective agents are utilized to treat balantidiasis.

Read Report Overview: https://www.transparencymarketresearch.com/balantidiasis-treatment-market.html

· Most of the people suffering from Balantidiasis are asymptomatic. Some people may become acutely ill with abnormally high temperatures, vomiting, nausea, abdominal pain, and bloody diarrhea. Such conditions could result in excessive loss of water from the body and extreme exhaustion, especially if B. coli attacks the intestinal lining causing inflammation and possibly ‘crater-like’ areas of damage. In serious cases, the ulcers could be deep enough to puncture the intestinal wall, resulting into the acute inflammation of the peritoneum?the membrane that lines the abdomen (peritonitis). Occasionally, the ulcer may diminish lung function.

· Tetracycline, a common antibiotic drug, is commonly prescribed in the treatment of Balantidiasis. When tetracycline cannot be administered, replacement drug therapy may include iodoquinol or metronidazole. It is not necessary to isolate the person suffering from Balantidiasis. However, the feces of infected individuals must be disposed of so that they don’t came into contact with drinking water or with food supplies.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56175

Key Drivers, Restraints, and Opportunities of Global Balantidiasis Treatment Market

· Rise in prevalence of balantidiasis infection, surge in the trend of swine farming, increase in research & development activities for the diagnosis of the disease, and surge in awareness about the treatment options are major factors that are projected to propel the balantidiasis diagnosis and treatment market during the forecast period. A study conducted by the Stanford University revealed that incidence of the infection has been reported in Bolivia, Papua New Guinea, and the Philippines. The prevalence rate of balantidiasis infection is lower than 1%. Lower incidence rate in major pharmaceutical markets such as North America and Europe and competition between already established players are likely to restrain the global balantidiasis diagnosis and treatment market, in terms of revenue, during the forecast period.

· Additionally, a lack of hygiene and sanitation in rural areas of developing countries is a significant factor that affects the spread of this disease. Furthermore, increasing awareness regarding the diseases transmitted via faecal-oral route further boosts the market. However, competition among existing market players hampers the entry of new players.

Request for Analysis of COVID19 Impact on Balantidiasis Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56175

Asia Pacific to Capture Major Share of Global Balantidiasis Treatment Market

Based on region, the global balantidiasis treatment market can be classified into North America (the U.S. and Canada), Europe (including Germany, France, and the U.K.), Asia Pacific (including Australia, China, Japan, and India), Latin America (including Brazil and Mexico), and Middle East & Africa (including GCC countries and South Africa). The disease is less prevalent in North America due to high sanitation standards and quality of living and hygienic environment. However, the disease is more prevalent in Latin America. Additionally, prevalence of the disease is low in Europe due to high hygiene standards, stringent quality control guidelines, hygienic food and water standards, and government support to maintain good hygiene. Asia Pacific and Latin America are emerging regions for the market; therefore, the market in these regions is projected to expand at a significant pace during the forecast period.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56175

Rapid expansion of the balantidiasis treatment market in these regions can be attributed to the increase in incidence of this infection, poor hygiene conditions, expansion of the healthcare industry, and rise in government investment to develop healthcare infrastructure in these regions. The balantidiasis treatment market in countries such as China, India, and Brazil is projected to expand at a high growth rate during the forecast period due to an increase in awareness among the population about protozoal infections and their treatments. Furthermore, the burden of gastrointestinal diseases is rising due to the increase in the number of pylori infection cases and changes in lifestyle such as consumption of alcohol, smoking, and sedentary work profile.

Pre-Book Balantidiasis Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=56175&ltype=S

Key Players Operating in Global Balantidiasis Treatment Market

The global balantidiasis treatment market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/inoculation-drives-to-attract-considerable-growth-for-the-disposable-syringes-market-auto-disposable-syringes-to-paint-bold-strokes-of-growth-tmr-301325488.html

https://www.prnewswire.com/news-releases/valuation-in-geriatric-medicines-market-to-reach-us-1142-8-bn-by-2027--use-in-managing-cardiovascular-diseases-spurs-growth-tmr-301331572.html

https://www.prnewswire.com/news-releases/asia-pacific-to-emerge-as-a-champion-growth-generating-region-for-the-antibacterial-drugs-market-due-to-escalating-government-initiatives-and-increasing-patient-population-tmr-insights-301333796.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

adityarana1687-blog · 3 years ago

Text

Helicobacter Pylori Diagnostics Market Expected To Achieve Lucrative Growth By 2026

The global helicobacter pylori diagnostics market size is anticipated to reach USD 759.0 million by 2026, according to a new report by Grand View Research. It is expected to expand at a CAGR of 6.0% over the forecast period. Increasing demand for personalized antibiotic therapy coupled with improved cost-effectiveness Helicobacter pylori (H. pylori) infection diagnosis is projected to drive the growth.

Easy accessibility and affordability of antibiotics along with short treatment durations will boost the adoption of antibiotics as well as the demand for pre and post monitoring tests. Furthermore, factors such as rising incidence of H. pylori infections, need for early diagnosis, and rapid technological advancements in diagnostic techniques will propel the market growth. However, rising pressure of maintaining economic pricing due to the extremely competitive environment may hinder the growth of the Helicobacter pylori diagnostics market.

H. pylori is an aerobic gram-negative bacteria generally found in the stomach. Although advantageous for balancing the stomach ecology, it can cause infection to the inner stomach lining. The bacteria can act as one of the causative agents for stomach cancer, duodenal ulcers, gastritis and gastric ulcers, and infection to the small intestine, among other conditions. This has led to an increase in the demand for Helicobacter pylori diagnostics that enable early detection of H. pylori infection. Patients are subject to an antibiotic therapy for 10 to 14 days, in case of positive diagnosis of ulcers caused by this bacteria. Treatment for H. pylori could include a combination of antibiotics such as metronidazole, amoxicillin, clarithromycin, tetracycline, or with a proton pump inhibitor, ranitidine bismuth citrate, and bismuth subsalicylate.

The immunoassay technology segment held the largest market share in 2018 and is expected to register the fastest CAGR over the forecast period. In terms of end user, the hospital segment held the largest market share in 2018, while diagnostic laboratories is anticipated to expand at the fastest CAGR in the forthcoming years. In terms of region, North America led the global market for Helicobacter pylori diagnostics. Asia Pacific, on the other hand, is expected to witness the fastest CAGR from 2019 to 2026.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/helicobacter-pylori-diagnostics-market

Further key findings from the study suggest:

Immunoassays technology held the largest market share in 2018 and is expected to witness the fastest CAGR over the forecast period

Among end user, hospital segment held the largest market share in 2018, while the diagnostics laboratories segment is expected to demonstrate the fastest CAGR from 2019 to 2026

Asia Pacific is projected to exhibit the fastest growth during the forecast period, attributed to increasing prevalence of infectious diseases, rising per capita healthcare expenditure, and improving healthcare infrastructure

Key players operating in the Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Biohit, Meridian Bioscience, Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Quest Diagnostics, Coris BioConcept, Certest Biotec, and Epitope Diagnostics

Grand View Research has segmented the global Helicobacter pylori diagnostics market on the basis of technology, end user, and region:

Helicobacter Pylori Diagnostics Technology Outlook (Revenue, USD Million, 2015 - 2026)

Immunoassays

POC

Molecular Diagnostics

Helicobacter Pylori Diagnostics End User Outlook (Revenue, USD Million, 2015 - 2026)

Hospitals

Diagnostics Laboratories

Clinics

Helicobacter Pylori Diagnostics Regional Outlook (Revenue, USD Million, 2015 - 2026)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

U.K.

Germany

France

Italy

Spain

Russia

Japan

China

India

South Korea

Singapore

Australia

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

#Helicobacter Pylori Diagnostics Market

0 notes

dopetrash · 4 years ago

Text

A Global Key Players - Overview

phenylbenzimidazole sulfonic acid is a very effective whitening ingredient used for acne treatment. The popularity of this compound is mostly based on its pungent odor, which some believe gives an unpleasant pleasant smell to the nose. However, other research reports indicate that this particular compound does not give off a bad odor and is actually quite pleasant to smell. This compound is also used in disinfection and deodorization.

Other benefits provided by the phenylbenzimidazole sulfonic acid include: protection against harmful UV rays and protection of DNA. It also has an anti-bacterial effect and is able to prevent bacterial growth when used on cuts and burns. It also blocks the formation of blisters and cuts, preventing infection and possible skin damage.

There are currently two main phenylbenzimidazole sulfonic acid products on the market, in liquid and cream form. These two products have different uses based on how they are used. The liquid form is less potent and should not be used in skin care products, unless prescribed by a doctor. Cream type products are more effective and can be used on the face and other various parts of the body, depending on what needs to be treated.

Sulfate-based phenylbenzimidazole sulfonic acid research products are used to fight fungal infections, athlete's foot, and nail infection. A sulfate crystal will produce a crystal white color and a high amount of salt will be released into the solution, which makes it easier for bacteria to adhere to the surface of the solution. Most products are marketed for a five day forecast period; however, there is a trend of longer duration forecast periods available for those that follow the directions properly.

The phenylbenzimidazole sulfonic acid market segmentation refers to the countries of north America. The primary product brands available in the US are Cetirizine, Prevacid, Metronidazole, Norpramin, and Phenaphen. The market in Canada is very competitive, with brands such as Metronidazole, Norpramin and Actonelia receiving high consumer ratings. In the UK, products such as Metronidazole, Actonel and Cipro have received high consumer acceptance and have formed a large part of the overall sulfate-based drugs market. Canada also has a large untapped market.

The International Nomenclature of Cosmetic Ingredients (INEC) classifies the phenylbenzimidazole sulfonic acid market as "coloring agents". The report offers classification guidelines for cosmetic products with this ingredient and notes that the compounds are generally colorless, yellow to brown and translucent. It is the strongest sunscreen pigment among the four sulfates and the first one to be approved by the US Environmental Protection Agency. The color change is due to the formation of a compound called Benzophenone.

It is the ability to block or absorb ultraviolet radiations (ultraviolet light) that makes Ensulizole (a derivative of phenylbenzimidazole sulfonic acid) an excellent sunscreen agent. It blocks most of the UVA and UVB radiation and thus protects against sunburns and other skin-damaging diseases. It also has a major effect on the bacteria responsible for acne. Research on healthy adults who were given regular doses of the sunscreen indicated that they had significantly lower frequencies of acne, while children who had been exposed to the sun were found to have significantly higher frequencies.

Ensulizole (is a derivative of phenylbenzimidazole sulfonic acid) is currently the most commonly used sunscreen agent for the treatment of melanoma. It is estimated that sales of sulfuric acid products are now exceeding those of all other ingredients in the key global players' product range combined. This indicates a very high demand for sulfuric acid products. As a consequence, competition in the sulfuric acid market is intense with many manufacturers vying for market share. As a result, the production value of sulfuric acid products is expected to grow very sharply in coming years.

Summary

The report forecast global Phenylbenzimidazole Sulfonic Acid market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation.

The report offers detailed coverage of Phenylbenzimidazole Sulfonic Acid industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Phenylbenzimidazole Sulfonic Acid by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

First, this report covers the present status and the future prospects of the global Phenylbenzimidazole Sulfonic Acid market for 2015-2024.

And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

At the same time, we classify Phenylbenzimidazole Sulfonic Acid according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Finally, the report provides detailed profile and data information analysis of leading Phenylbenzimidazole Sulfonic Acid company.

Key Content of Chapters as follows (Including and can be customized) :

Part 1:

Market Overview, Development, and Segment by Type, Application & Region

Part 2:

Company information, Sales, Cost, Margin etc.

Part 3:

Global Market by company, Type, Application & Geography

Part 4:

Asia-Pacific Market by Type, Application & Geography

Part 5:

Europe Market by Type, Application & Geography

Part 6:

North America Market by Type, Application & Geography

Part 7:

South America Market by Type, Application & Geography

Part 8:

Middle East & Africa Market by Type, Application & Geography

Part 9:

Market Features

Part 10:

Investment Opportunity

Part 11:

Conclusion

Market Segment as follows:

By Region

Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East & Africa[GCC, North Africa, South Africa]

South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Companies

BASF SE

DSM

J&K Scientific

Shanghai Hanhong Chemical

Berje Inc

Changzhou Sunchem Pharmaceutical Chemical Material

Masteam Bio-tech

Hairui Chemical

Market by Type

Purity ?95%

Purity ?97%

Purity ?98%

Purity ?99%

Market by Application

Sunscreens

Lotions

Moisturizers

Others

Global Phenylbenzimidazole Sulfonic Acid Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.

Global Phenylbis Phosphine Oxide Market

Global Pheromones in Agriculture Market

Global Phone Arm Package Market

#phenylbenzimidazole sulfonic acidphenylbenzimidazole sulfonic acid Researchphenylbenzimidazole sulfonic acid Research Reportsphenylbenzimida

0 notes

rohans18 · 1 year ago

Text

Trichomoniasis Drugs Market Key Players, Outlook and Forecast 2030

Global Trichomoniasis Drugs Market, By Drug Type (Metronidazole, Tinidazole), Product Type ((Tablet, Suppository/Pessaries, Cream, IV), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Trichomoniasis Drugs marketing report. The report has a lot to offer to both established and new players in the Trichomoniasis Drugs industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Trichomoniasis Drugs market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

Pfizer Inc. (U.S.)

Lupin (India)

Teva Pharmaceuticals Industries Ltd. (Israel

Zydus Group (India)

Bausch Health Companies Inc (Canada)

Missionpharma A/S (Denmark)

Zauba Technologies & Data Services Private Limited (India)

Mission Pharmacal Company (U.S.)

Unique Pharmaceuticals Limited.(Africa)

Edenbridge Pharmaceuticals, LLC (U.S.)

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-trichomoniasis-drugs-market

With the help of credible Trichomoniasis Drugs market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Trichomoniasis Drugs market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Trichomoniasis Drugs Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

0 notes

athiranair23 · 4 years ago

Text

Animal Healthcare Market Analysis (2020-2027)

Animal healthcare focuses on effective animal health management through diagnosis and treatment of various diseases in animals.

Statistics:

The global animal healthcare market is estimated to account for US$ 61,168.31 Mn in terms of value by the end of 2027

Global Animal Healthcare Market: Drivers

Increasing consumption of meat, milk and other animal byproducts is expected to boost growth of the global animal healthcare market over the forecast period. For instance, the USDA National Agricultural Statistics Service (NASS) estimated November 2019 U.S. milk production at 17.440 billion pounds, 0.5 percent higher than November 2018.

Moreover, increasing prevalence of foodborne and zoonotic diseases is also expected to propel growth of the market. For instance, according to May 2019 report of the Centers of Disease Control and Prevention (CDC), salmonella infection (salmonellosis) causes approximately 1.2 million illnesses and 450 deaths annually, in the U.S. and in 2018, there were 18 reported outbreaks, 15 of which were linked to food.

Statistics:

North America held dominant position in the global animal healthcare market in 2019, accounting for 33.1% share in terms of value, followed by Europe and Asia Pacific, respectively

Figure 1. Global Animal Healthcare Market Share (%), by Region, 2019

Source: Coherent Market Insights Analysis (2020)

Global Animal Healthcare Market: Restraints

A lack of surveillance and diagnostics for zoonotic diseases in developing economies is expected to hinder growth of the global animal healthcare market.

Moreover, stringent regulations over use of antibiotics in animal feed is also expected to limit growth of the market. For instance, in the U.S. state of California Senate Bill 27—known as SB 27—aims to minimize the feeding of antibiotics to animals and it prohibits the use of antibiotics “solely for purposes of promoting weight gain or improving feed efficiency.”

Statistics:

The Production Animal segment was valued at US$ 26,374.5 Mn in 2019 and is forecast to reach a value of US$ 39,159.8 Mn by 2027 at a CAGR of 5.1% between 2019 and 2027

Market Trends/Key Takeaways

In the U.S., beef export has declined, which is expected to hinder growth of the market. For instance, according to the USDA National Agricultural Statistics Service (NASS), in November 2019, beef exports from the U.S. totaled 245 million pounds, 21 million pounds below the November 2018 total.

Asia Pacific is expected to witness significant growth in the market, owing to increasing production of milk. For instance, according to the UN's Food and Agriculture Organization (FAO), in 2018, India produced 186 million tons of milk, which was 22% of that year's global total milk production of 843 million tons.

Regulations

North America

In order to reduce the use of antibiotics as growth promoters in animals, the Danish Veterinary and Food Administration (DVFA) restricted the use of fluoroquinolones (banned) and cephalosporins in 2002. In 2010, an industrial voluntary ban (Sweden, France and Denmark) on the use of cephalosporins was implemented for a 2-year period, and a Yellow Card initiative was implemented in Denmark, targeting the largest consumers of antibiotics in the swine production industry. As a result, the consumption of antibiotics from January 2011 to June 2011 was 25 % lower compared to the same period the previous year.

2005: FDA banned the use of Baytril – a fluoroquinolone antibiotic – also known as enrofloxacin – in chicken and turkey. The antibiotic leads to the emergence of antibiotic resistant bacteria such as Campylobacter in humans, as its chemical composition is similar to that of Cipro – a human antibiotic – which is a common prescription drug to treat foodborne illnesses in humans.

2012: Maryland banned the usage of arsenic-based drugs in chicken feed. However, it is used across other states in the U.S. The drug received FDA approval as its arsenic content is within safe limits for human consumption.

2014: The FDA directed 26 major pharmaceutical companies in the U.S. to cease production of weight-gain drugs for animals by December 2016. It further directed the companies to stop OTC sales of antimicrobials such as Roxarsone (sold under the brand 3-Nitro) administered to livestock through feed and water, which are also used in human medicine. The objective of this move is to reduce health risks associated with the consumption of antimicrobial treated meat products.

Ractopamine hydrochloride – a growth promoter drug – is banned in Europe and 160 other countries such as China, Taiwan, Russia, India, Turkey, Iran, Egypt, Kenya and Zimbabwe. However, its use is permitted in the U.S., Brazil and Canada to increase muscle production in swine, turkey and cattle. Since December 2012, meat imports in Russia from countries such as the U.S. is subject to ractopamine-free certification.

U.S.

GROUP I. Drugs with No Allowable Extra-label Uses in Any Food-producing Animal Species

CHLORAMPHENICOL

CLENBUTEROL

DIETHYLSTILBESTEROL (DES)

FLUOROQUINOLONE–CLASS ANTIBIOTICS

GLYCOPEPTIDES — all agents, including VANCOMYCIN

MEDICATED FEEDS

NITROIMIDAZOLES-all agents, including DIMETRIDAZOLE, IPRONIDAZOLE, METRONIDAZOLE and others

NITROFURANS — all agents, including FURAZOLIDINE, NITROFURAZONE and others

GROUP III. Drugs with Special Restrictions for Grade "A" Dairy Operations

· Grade A Pasteurized Milk Ordinance

· NON-MEDICAL GRADE DIMETHYLSULFOXIDE (DMSO) — no use or storage allowable

· DIPYRONE — no use allowable

· COLLOIDAL SILVER — no use or storage allowable

· SYSTEMICALLY–ACTING DRUGS THAT ARE APPLIED TOPICALLY (including Fenthion, Famphur and Xylene, Phosmet, Levamisole and all ivermectins and avermectins — no use allowable

GROUP II. Drugs with Restricted Extra-Label Uses in Food-Producing Animal Species

· ADAMANTANE & NEURAMINIDASE INHIBITORS in all poultry, including ducks – these agents are approved for treatment or prevention of influenza A

· CEPHALOSPORIN–CLASS ANTIBIOTICS except CEPHAPIRIN in all classes of cattle, chickens, pigs and turkeys – ELDU restrictions apply to ALL PRODUCTION CLASSES OF MAJOR FOOD-ANIMAL SPECIES.

1. 1) No ELDU for purpose of disease prevention

2. 2) No ELDU that involves unapproved dose, treatment duration, frequency or administration route

3. 3) Agent must be approved for that species and production class

– ELDU restrictions DO NOT APPLY to minor–use food animal species.

· GENTIAN VIOLET — prohibited for use in food or feed of food-producing animal species

· INDEXED DRUGS — some exceptions for minor-use species

· PHENYLBUTAZONE — in female dairy cattle (20 months of age or older)

· SULFONAMIDE–CLASS ANTIBIOTICS — in lactating dairy cattle– approved uses are allowed for Sulfadimethoxine, Sulfabromomethazine and Sulfaethoxypyridazine

Segmentation:

Global Animal Healthcare Market: Competitive Landscape

Major players operating in the global animal healthcare market include, Bayer AG, Boehringer Ingelheim GmbH, Cargill, Inc., Ceva Santé Animale, Eli Lilly and Company, Koninklijke DSM N.V., Merck & Co., Inc., Novartis AG, Nutreco N.V., Sanofi S.A., SeQuent Scientific Ltd., Virbac S.A., Vétoquinol S.A., and Zoetis Inc.

Global Animal Healthcare Market: Key Developments

Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in 2018, Boehringer Ingelheim Animal Health collaborated with Kamraan Veterinary Medicine Co. Group, a veterinary medicine wholesaler and retailer in U.A.E, for marketing veterinary medicines.

Major players in the market are also focused on launching new products to expand their product portfolio. For instance, in March 2020, Kinetic Vet, an animal health company, launched ArmourGuard RTU, an EPA-approved spray-on antimicrobial biosecurity solution that provides continual antimicrobial activity against microorganisms for up to 90 days.

Request sample copy here :

https://www.coherentmarketinsights.com/insight/request-sample/3708

Request PDF brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/3708

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

· Customized Market Research Services

· Industry Analysis Services

· Business Consulting Services

· Market Intelligence Services

· Long term Engagement Model

· Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email : [email protected]

Reference/Source: https://www.coherentmarketinsights.com/

#CoherentMarketInsights #MarketAnalysis #Healthcare #diagnosis #healthmanagement #AnimalHealthcareMarketAnalysis

0 notes

vivekbajaj-grs · 3 years ago

Text

Global Metronidazole Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.

Global Metronidazole key players include CordenPharma Farchemia, Tongji Pharmaceutical, Aarti Drugs, Manav Drugs, etc.

China is the largest market, with a share about 90%, followed by India, and Europe, both have a share over 10 percent.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-metronidazole-2021-2027-582

In terms of product, Glyoxal Process is the largest segment, with a share over 85%. And in terms of application, the largest application is Metronidazole Tablets, followed by Metronidazole Capsule, Metronidazole Injection, etc.

Market Analysis and Insights: Global Metronidazole Market

In 2020, the global Metronidazole market size was US$ 114 million and it is expected to reach US$ 109.7 million by the end of 2027, with a CAGR of -0.5% during 2021-2027.

Global Metronidazole Scope and Market Size

Metronidazole market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Metronidazole market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Metronidazole market is segmented into

Glyoxal Process

Ethidene Diamine Process

Others

Segment by Application, the Metronidazole market is segmented into

Metronidazole Tablets

Metronidazole Capsule

Metronidazole Injection

Others

Regional and Country-level Analysis:

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape and Metronidazole Market Share Analysis

Metronidazole market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Metronidazole product introduction, recent developments, Metronidazole sales by region, type, application and by sales channel.

The major companies include:

Hongyuan Pharmaceutical

Yinhe Aarti Pharmaceutical

Saikang Pharmaceutical

Zhongan Pharmaceutical

Wuyao Pharmaceutical

Yichang Changjiang Pharmaceutical

Tongji Pharmaceutical

Hongda Pharmaceutical

Topsun Pharmaceutical

Unichem Laboratories

CordenPharma Farchemia

API Polpharma

Manav Drugs

Aarey Drugs & Pharmaceuticals

Aarti Drugs

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-metronidazole-2021-2027-582

Table of content

1 Study Coverage 1.1 Metronidazole Product Introduction 1.2 Market by Type 1.2.1 Global Metronidazole Market Size Growth Rate by Type 1.2.2 Glyoxal Process 1.2.3 Ethidene Diamine Process 1.2.4 Others 1.3 Market by Application 1.3.1 Global Metronidazole Market Size Growth Rate by Application 1.3.2 Metronidazole Tablets 1.3.3 Metronidazole Capsule 1.3.4 Metronidazole Injection 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Metronidazole Market Size Estimates and Forecasts 2.1.1 Global Metronidazole Revenue 2016-2027 2.1.2 Global Metronidazole Sales 2016-2027 2.2 Metronidazole Market Size by Region: 2021 Versus 2027 2.3 Metronidazole Sales by Region (2016-2027) 2.3.1 Global Metronidazole Sales by Region: 2016-2021 2.3.2 Global Metronidazole Sales Forecast by Region (2022-2027) 2.3.3 Global Metronidazole Sales Market Share by Region (2016-2027) 2.4 Metronidazole Market Estimates and Projections by Region (2022-2027) 2.4.1 Global Metronidazole Revenue by Region: 2016-2021 2.4.2 Global Metronidazole Revenue Forecast by Region (2022-2027) 2.4.3 Global Metronidazole Revenue Market Share by Region (2016-2027) 3 Global Metronidazole by Manufacturers 3.1 Global Top Metronidazole Manufacturers by Sales 3.1.1 Global Metronidazole Sales

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

#MetronidazoleMarket

0 notes

sriramnanda-blog · 4 years ago

Text

ANIMAL HEALTHCARE MARKET ANALYSIS

Animal healthcare focuses on effective animal health management through diagnosis and treatment of various diseases in animals.

Statistics:

The global animal healthcare market is estimated to account for US$ 61,168.31 Mn in terms of value by the end of 2027

Global Animal Healthcare Market: Drivers

Statistics:

North America held dominant position in the global animal healthcare market in 2019, accounting for 33.1% share in terms of value, followed by Europe and Asia Pacific, respectively

Figure 1. Global Animal Healthcare Market Share (%), by Region, 2019

Source: Coherent Market Insights Analysis (2020)

Global Animal Healthcare Market: Restraints

A lack of surveillance and diagnostics for zoonotic diseases in developing economies is expected to hinder growth of the global animal healthcare market.

Statistics:

The Production Animal segment was valued at US$ 26,374.5 Mn in 2019 and is forecast to reach a value of US$ 39,159.8 Mn by 2027 at a CAGR of 5.1% between 2019 and 2027

Market Trends/Key Takeaways

Regulations

North America

U.S.

GROUP I. Drugs with No Allowable Extra-label Uses in Any Food-producing Animal Species

CHLORAMPHENICOL

CLENBUTEROL

DIETHYLSTILBESTEROL (DES)

FLUOROQUINOLONE–CLASS ANTIBIOTICS

GLYCOPEPTIDES — all agents, including VANCOMYCIN

MEDICATED FEEDS

NITROIMIDAZOLES-all agents, including DIMETRIDAZOLE, IPRONIDAZOLE, METRONIDAZOLE and others

NITROFURANS — all agents, including FURAZOLIDINE, NITROFURAZONE and others

GROUP III. Drugs with Special Restrictions for Grade "A" Dairy Operations

Grade A Pasteurized Milk Ordinance

NON-MEDICAL GRADE DIMETHYLSULFOXIDE (DMSO) — no use or storage allowable

DIPYRONE — no use allowable

COLLOIDAL SILVER — no use or storage allowable

SYSTEMICALLY–ACTING DRUGS THAT ARE APPLIED TOPICALLY (including Fenthion, Famphur and Xylene, Phosmet, Levamisole and all ivermectins and avermectins — no use allowable

GROUP II. Drugs with Restricted Extra-Label Uses in Food-Producing Animal Species

ADAMANTANE & NEURAMINIDASE INHIBITORS in all poultry, including ducks – these agents are approved for treatment or prevention of influenza A

CEPHALOSPORIN–CLASS ANTIBIOTICS except CEPHAPIRIN in all classes of cattle, chickens, pigs and turkeys – ELDU restrictions apply to ALL PRODUCTION CLASSES OF MAJOR FOOD-ANIMAL SPECIES.

1) No ELDU for purpose of disease prevention

2) No ELDU that involves unapproved dose, treatment duration, frequency or administration route

3) Agent must be approved for that species and production class

– ELDU restrictions DO NOT APPLY to minor–use food animal species.

GENTIAN VIOLET — prohibited for use in food or feed of food-producing animal species

INDEXED DRUGS — some exceptions for minor-use species

PHENYLBUTAZONE — in female dairy cattle (20 months of age or older)

SULFONAMIDE–CLASS ANTIBIOTICS — in lactating dairy cattle– approved uses are allowed for Sulfadimethoxine, Sulfabromomethazine and Sulfaethoxypyridazine

Segmentation:

Global Animal Healthcare Market: Competitive Landscape

Global Animal Healthcare Market: Key Developments

About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah

Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]

0 notes

vsplusonline · 5 years ago

Text

Trade in the time of Coronavirus: Sectors overdependent on Chinese imports face a grim reality

New Post has been published on https://apzweb.com/trade-in-the-time-of-coronavirus-sectors-overdependent-on-chinese-imports-face-a-grim-reality/

Trade in the time of Coronavirus: Sectors overdependent on Chinese imports face a grim reality

As fresh cases of the Coronavirus (COVID-19) raises fears of a global pandemic, the impact of the shutdown across China has started to hit Indian businesses, some very severely.

With the province of Hubei and eastern parts of China taking a big hit, key industries in India that depend on imports, are coming to a grinding halt. The story is not so bad for India’s exports to China, but imports to several industries are feeling the strain.

According to Crisil, about 18% of India’s total merchandise imports are from China. India had a trade deficit of $159 billion as of calendar 2019 and it remains a net importer from China (including Hong Kong) of $56 billion. In this backdrop, the worst hit are industries in electronics, consumer durables, auto components and pharma.

Short circuit The sector that is under severe stress is the electronics industry. A significant share of inputs required in electronics components manufacturing has traditionally been sourced from China.

“As a result of the Coronavirus outbreak, the sector is in dire strait as the entire supply chain is now severely affected. Even those supplies that have already arrived in India require an advanced level of sanitisation before they are allowed to be dispatched to various markets. The tragedy is, no worker is willing to touch any device sourced from China as of now,” says Rajoo Goel, Secretary General, Electronic Industries Association of India (Elcina).

The crisis is now across the value chain. There are thousands of electronics manufacturing services (EMS) manufacturers bought from India, and now their supply chain is, in turn, affected. “From mobile phone manufacturing to printers, to PCs to set-up boxes and inverters are being affected since PCBs were being sourced from China. These were just being assembled in India. Similarly, aluminium, copper and chemicals in electronics manufacturing were sourced from China. For a large number of electronics manufacturers, it’s still much easier, and financially viable to import the Semi Knocked Down (SKD) or Completely Knocked Down (CKD) equipment from China,” says Goel.

He adds that the situation is so grave that in next 10-15 days, the industry will be able to utilise only 50% of new production capacities and in the next three weeks, there is a possibility of a complete lockdown across various manufacturing plants.

Problems for the players in the sector are compounded since other countries in the region do not want to fill the gap. “It will be a major lockdown because, if instead of China, a player thinks of importing from, say, Japan or Taiwan then, the suppliers don’t want to entertain Indian importers because they know the new demand generated as a result of the Coronavirus is temporary,” says Goel.

In the next 30 days, all electronic equipment will turn dearer by 20-30 %, including mobile phones, among others. Experts say this issue will hamper the sector for 3-6 months.

Image Source: Crisil

Bitter pill Another sector that is facing the brunt because of its over reliance on China is the pharma sector.

According to the Trade Promotion Council of India, approximately 85% of active pharmaceutical ingredient (API) imported by India are from China. India’s overdependence on China for APIs exposes it to raw material supply disruption and price volatility. Notably, China accounted for around 67% of total imports of bulk drugs and drug intermediates in 2018-19. India has a high dependence on fermentation-based APIs/intermediates namely antibiotics and vitamins.

“Representative of Pharmexcil informed that in all 58 molecules are imported from China, out of which 12 are imported from the Hubei province which is affected by the Coronavirus. Areas beyond 500 km from Wuhan may possibly start dispatching KSM’s & API’s in about 2-3 weeks, while Wuhan city itself might take about 8 weeks or thereabouts to bring about normalcy to some extent,” says Satish Wagh, ex-Chairman, Chemexcil

Wagh adds that 16 molecules will be affected to a large extent such as certain antibiotics like Chloramphenicol, Erythromycin, Azithromycin, Clarithromycin, Amoxicillin, Vitamins A B, E & C & E, hormones like Progesterone, Metronidazole etc. “India may have to go slow on exports of formulations based on these molecules so as to ensure adequate supplies for India irrespective of other international commitments. In case of such commitments to the foreign suppliers force majeure clause can be initiated,” says Wagh.

Anil Bhardwaj, Secretary General, Federation of Indian Micro and Small & Medium Enterprises (FISME), says the import of APIs is critical for pharma industry and its shortage will cripple pharma manufacturing.

“There is no one remedy to contain this impending crisis. I think solutions would be sector specific. For API, India may have to develop its own sources within the country. A lot of Government support is needed to realize this and it could turn out to be an opportunity,” says Bhardwaj.

Leather hunt Another sector that has massive levels of ‘essential Imports’ is the leather goods manufacturing sector. “There are many global buyers who strictly adopt the practice of nominating China-based suppliers for their final orders that are made here in India. So such orders will be negatively impacted. There are a whole lot of enhancements/ add-ons related to uniform packaging, labelling etc. needed for final products and there certainly is going to be an impact on such supplies,” says Puran Chand Dawar Regional Chairman (North), Council for Leather Exports (CLE) and President, Agra Footwear Manufacturers and Exporters Chamber (AFMEC).

What is clear is that business players in the leather sector need to re-strategize their long term roadmaps as a result of the Coronavirus outbreak. “In a nutshell, I would say, the lesson from the Coronavirus outbreak is that in the long run, Indian importers need to shun their long-held practice of putting ‘all eggs in one basket’ attitude. They need to diversify their risks and can’t depend on one single market to meet their 70-80% of their sourcing demands. They need to explore other markets too, even if those are currently dearer by a few percentage points. This will help them better tackle any such future irregularity in their supply chains,” says Dawar.

Image Source: Crisil

Not all bad If dwindling imports have led to a crisis situation across many sectors, some in exports are expected to benefit.

“India will now be looked upon as a short to long term option. India is poised to gear up for production in the short-term with the low-end and medium-end products are expected to benefit well. Carpets will benefit and so will furniture and handicraft categories. If the situation continues this way, we expect India’s exports to see a 10-15% growth next year,” says Mahavir Pratap Sharma, Past Chairman, Carpet Export Promotion Council (CEPC).

According to Rakesh Kumar, Director General, Export Promotion Council for Handicrafts (EPCH), as far as exports are concerned, it is a major emerging opportunity for India. “There are some major trade shows that happen in Germany and other markets, where the participation of Chinese delegates and buyers have been next to negligible now. In 2020 seasons of summer, winter and fall, no surplus of Chinese products are expected. This situation is a definite opportunity – buyers are thinking about an alternative supply source. That may not necessarily be India and can be markets like Vietnam, Indonesia or Malaysia as well. One has to have a first mover approach to be ahead of the curve,” says Kumar.

Kumar adds that he does not see the situation improve in China before Q3 of 2020, but it is important to note that not everyone will have faith in India as capacity building has been an issue. “We can do better with mid segment buyers where capacity building does not come into play. For the large segment, confidence is still in question as far as the Indian market is concerned. We will do better for higher value and niche segment (handmade) where our strengths will also come into focus. The next two months will be quite important, but the sentiments are positive,” says Kumar.

However, what is not clear is the knock on effect of the virus. With many countries in Europe seeing a spike in cases, the perceived benefits from exports may not materialize if the global economy starts slowing down and demand takes a hit.

“Various industry bodies/trade bodies like FIEO, Chemexcil, ACMA need to urgently start analysing the sector-wide impact of the Coronavirus outbreak on their respective sectors. At the moment, the biggest bottleneck is that the information coming out of China cannot be trust completely. The real impact of the health hazards could be more than what’s being told at the moment,” says Mahendra Sanghi, Ex-President, Assocham and Group Chairman, Sanghi Group of Industries.

if(geolocation && geolocation != 5 && (typeof skip == 'undefined' || typeof skip.fbevents == 'undefined')) !function(f,b,e,v,n,t,s) if(f.fbq)return;n=f.fbq=function()n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments); if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '338698809636220'); fbq('track', 'PageView');

Source link

#Business

0 notes

myabhijitr · 6 years ago

Text

Amebiasis Treatment Market Industry Size, Share, Outlook, and Forecast 2018-2026

Amebiasis can lead to diarrhea (with or without blood) in both adults and children, leading to high morbidity and mortality. The organism, Entamoeba Histolytica, can damage organ and may require surgical intervention, if the colon and other tissues have undergone perforation. However, amebiasis can be treated with some antibiotic, anti- parasitic, and antiprotozoal drugs such as metronidazole, paromomycin, and tinidazole. Diagnosis of this disease is usually made by microscopic identification of the microorganism in a stool specimen.

Increasing approvals and launches of new drugs indicated for the treatment of amebiasis is expected to be a major factor for growth of amebiasis treatment market. For instance, in 2017, Dr. Reddy's Laboratories received U.S. Food and Drug Administration (FDA) approval for its Minolira (minocycline) extended-release tablets, indicated for the treatment of a variety of bacterial infections and as adjunctive therapy in acute intestinal amebiasis.

Request Sample Report@ https://www.coherentmarketinsights.com/insight/request-sample/1595

Moreover, in 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Metronidazole Tablets, 250mg and 500mg, generic version of Flagyl manufactured by G.D. Searle, LLC’s, indicated for the treatment of amebiasis and a variety of anaerobic bacterial infections. In 2016, Mylan Pharmaceuticals Inc. received ANDA approval for its Doryx (Doxycycline Hyclate) Delayed-Release Tablets, 50 mg, indicated for the treatment of acute intestinal amebiasis. Furthermore, increasing prevalence of amebiasis in region with poor sanitation facilities such as Africa and some countries in Asia Pacific is expected to lead to increasing demand for its treatment, which in turn is expected to drive growth of the amebiasis treatment market in the near future.

For instance, according to data published by International Research Journal of Biological Sciences, in 2013, the prevalence of amebiasis among school children in Lafia, Nigeria was around 26.7%. The highest prevalence of amebiasis was 40.0% in children of Government Secondary School Tudun Kauri, Lafia. This high prevalence of amebiasis was due to poor environmental/drainage system, unhygienic methods of disposing sewage, and shortage of clean water supply.

Click to view the full report TOC, figure and tables: https://www.coherentmarketinsights.com/ongoing-insight/toc/1595

Africa is expected to show a significant growth in the global amebiasis treatment market over the forecast period, owing to high prevalence rate of amebiasis due to poor sanitation and low availability of clean drinking water. For instance, according to data published by United Nations Department of Economic and Social Affairs (UNDESA), in 2014, around 115 people in Africa die every hour from diseases linked to poor sanitation, poor hygiene, and contaminated water.

In Sub-Saharan Africa around 40% of the 783 million people do not have access to a clean source of drinking water. Furthermore, Asia Pacific region is expected to show significant growth in amebiasis treatment market over the forecast period, owing to increasing prevalence of amebiasis in some rural areas of India and China. For instance, according to data published on National Health Portal of India, in 2015, amebiasis affected about 15% of the total population in India.

Key players operating in amebiasis treatment market include Pfizer Inc., Impax Laboratories, Lupin Pharmaceuticals, Inc., Sanofi, Actelion Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Inc., Heritage Pharmaceuticals Inc., Mission Pharmacal Co., Novel Laboratories, and others. Key players in the market are focusing on launching generic versions of branded medicines indicated for treatment of amebiasis. For instance, in 2017, Mayne Pharma Group Limited received FDA approval for its Doxycyline Hyclate IR Tablets, first generic to Acticlate. Doxycycline Hyclate 75 mg and 150 mg are tetracycline class drugs indicated for adjunctive therapy for acute intestinal amebiasis.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/amebiasis-treatment-market-1595

#amebiasis treatment market #amebiasis treatment market size #amebiasis treatment market outlook

0 notes

clevertimetravelpaper · 2 years ago

Text

Bacterial Vaginosis Treatment Market Receives a Rapid Boost in Economy due to High Emerging Demands by Regional Forecast

Bacterial vaginosis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of vaginal infection in females worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of vaginal infection in females due to unhygienic reproductive health, increased smoking, infected partner and excessive use of vaginal deodorants & douche drives the bacterial vaginosis treatment market. However, increased awareness related female reproductive health, rise in prevalence of vaginal infection especially in pregnant women & adults and rise in prevalence of other STDs will boost up the global bacterial vaginosis treatment market. Furthermore, lack of infection awareness in developing countries and homemade treatment for infection may hamper the global bacterial vaginosis treatment market.

Get a Sample PDF of the report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bacterial-vaginosis-treatment-market

Bacterial vaginosis is the infection of vagina that happened when there’s a change in the normal balance of bacteria present in the vagina. Symptom includes burning feeling, fishy smell, itching, thin white, grey, or green discharge. Females having bacterial vaginosis are at higher risk of getting other STDs. In 2001-2004 the prevalence in the United States is estimated to be 21.2 million (29.2%) among women ages 14–49, based on a nationally representative sample of women who participated in NHANES.

This bacterial vaginosis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Bacterial Vaginosis Treatment Market Scope and Market Size

The bacterial vaginosis treatment market is segmented on the basis of treatment, dosage form, route of administration, end-users and distribution channel.

On the basis of treatment, the bacterial vaginosis treatment market is segmented into medication, and others. Medication further divided into antibiotics such as metronidazole, clindamycin, tinidazole and others.

On the basis of dosage form, the bacterial vaginosis treatment market is segmented into creams, gel, pills, solution/washes, injection and others

Route of administration segment of bacterial vaginosis treatment market is segmented into oral, parenteral, vaginal and others

On the basis of end-users, the bacterial vaginosis treatment market is segmented into hospitals, specialty clinics and others

On the basis of distribution channel, the bacterial vaginosis treatment market has also been segmented into hospital pharmacy, retail pharmacy others

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@-

Bacterial Vaginosis Treatment Market Country Level Analysis

Bacterial vaginosis treatment is analysed and market size information is provided by country, treatment, dosage form, route of administration, end-users and distribution channel as referenced above. The countries covered in the bacterial vaginosis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as part of Middle East and Africa.

North America accounts the highest market share due to increased prevalence of vaginal infections in female and affordable reimbursement scenario encourages growth. Europe is considered second largest market for bacterial vaginosis treatment due to strategic collaboration between academic research institute and pharmaceutical giants to develop new drugs. Asia-Pacific is expected to account for the largest market share over coming years for the bacterial vaginosis treatment market to presence of generic manufacturers and increased female population.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Bacterial Vaginosis Treatment Market Share Analysis

Bacterial vaginosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bacterial vaginosis treatment market.

The major players covered in the bacterial vaginosis treatment market are Teva Pharmaceutical Indutries Ltd., Pfizer Inc., Baxter, B. Braun Melsungen AG, Bausch Health Companies Inc., Tolmar Pharmaceuticals Inc., Perrigo Company Plc., Missionpharma A/S, and Hikma Pharmaceutical PLC among others.

Browse the complete table of contents at- https://www.databridgemarketresearch.com/toc/?dbmr=global-bacterial-vaginosis-treatment-market

Top Healthcare Reports:

North America Anesthesia and Respiratory Devices Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/north-america-anesthesia-and-respiratory-devices-market

Europe Anesthesia and Respiratory Devices Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/europe-anesthesia-and-respiratory-devices-market

North America Lab Automation Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/north-america-lab-automation-market

Europe Lab Automation Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/europe-lab-automation-market

Asia-Pacific Lab Automation Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/asia-pacific-lab-automation-market

Total Lab Automation Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-total-lab-automation-market

Network Test Lab Automation Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-network-test-lab-automation-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- [email protected]

0 notes

ihealthcareanalyst · 8 years ago

Text

Global Periodontal Disease Therapeutics Market USD 160 Million by 2020

Research in recent years in periodontology has seen a shift from surgery towards medicine. Scaling and root planing is sometimes followed by adjunctive therapy such as local delivery antimicrobials, systemic antibiotics, and host modulation, as needed on a case-by-case basis. The antimicrobials have included metronidazole in an ointment form (Elyzol), chlorhexidine (Periochip) as well as doxycycline either in a fiber form (Actisite), or also in a polymeric delivery system (Atridox).

The global periodontal disease therapeutics market is estimated to reach USD 160 Million in 2020, growing at a CAGR of 8.2% from 2016 to 2020, according to a market research report Periodontal Disease Therapeutics Market, 2016-2020, published by iHealthcareAnalyst, Inc.

Visit the Periodontal Disease Therapeutics Market, 2016-2020 report at https://www.ihealthcareanalyst.com/report/periodontal-disease-therapeutics-market/

The global periodontal disease therapeutics market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).

The global periodontal disease therapeutics market segmentation is based on drug types (Arestin, Atridox, Doxycycline, Metronidazole, Minocycline, PerioChip). The global periodontal disease therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Drug Type

Arestin

Atridox

Doxycycline

Metronidazole

Minocycline

PerioChip

Geography (Region, Country)

North America (U.S., Canada)

Latin America (Brazil, Mexico, Rest of LA)

Europe (U.K., Germany, France, Italy, Spain, Rest of EU)

Asia Pacific (Japan, China, India, Rest of APAC)

Middle East

Rest of the World

Company Profiles

DenMat Holdings, LLC

Dexcel

Galderma S.A.

Kaken Pharmaceuticals Co., Ltd

Valeant Pharmaceuticals

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: [email protected] Website: https://www.ihealthcareanalyst.com

- https://www.ihealthcareanalyst.com/global-periodontal-disease-therapeutics-market/

0 notes